Tissue Culture Media Supplemented With 10% Fetal Calf Serum Contains a Castrate Level of Testosterone

被引:79
作者
Sedelaar, J. P. Michiel [1 ]
Isaacs, John T. [1 ,2 ]
机构
[1] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD 21231 USA
[2] Johns Hopkins Univ, Sch Med, James Buchanan Brady Urol Inst, Dept Urol, Baltimore, MD 21231 USA
关键词
cell culture; testosterone; castration levels; auto-regulation; ANDROGEN DEPRIVATION THERAPY; RECURRENT PROSTATE-CANCER; CELL-LINES; BINDING GLOBULIN; RECEPTOR; DIHYDROTESTOSTERONE; PLASMA; CHROMATOGRAPHY; SUPPRESSION; COMPENDIUM;
D O I
10.1002/pros.21028
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. Human prostate cancer cells are routinely maintained in media supplemented with 10% Fetal Calf Serum (FCS) to provide androgen. In the present study, total and free testosterone levels in 10%FCS supplemented tissue culture media were determined and compared to levels in intact and castrated human males. Dextran-coated charcoal stripped FCS (i.e., DC-FCS) is often used instead of FCS to minimize the level of androgen provided in 10% serum supplemented media. Therefore, total and free testosterone levels in 10%DC-FCS containing media were likewise determined. METHODS. Total testosterone, free testosterone, and total dihydrotestosterone (DHT) were determined on RPMI-1640 media supplemented with either 10%FCS or 10%DC-FCS by ELISA assays before and after exposure to LNCaP human prostate cancer cells in culture. The growth and PSA secretion by these cells was also determined. RESULTS. Ten percentage FCS supplemented media contains a castrate level of testosterone. However, even with this castrate starting level of testosterone, LNCaP cells concentrate and metabolize the testosterone to produce a physiologic (i.e., 10 nM) level of intracellular DHT which optimally stimulates the growth of these cells in vitro. CONCLUSIONS. The present studies document that prostate cancer cells auto-regulate their androgen metabolism so that an optimal level of DHT for growth is maintained during both up and down fluctuations in the supply of testosterone. These results have significant implications for whether exogenous androgen should be added to the 10%FCS supplemented media to grow prostate cancer cells from intact versus castrated patients. Prostate 69: 1724-1729, 2009. (C) 2009 Wiley-Liss, Inc.
引用
收藏
页码:1724 / 1729
页数:6
相关论文
共 31 条
[1]   Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone [J].
Askew, Emily B. ;
Gampe, Robert T., Jr. ;
Stanley, Thomas B. ;
Faggart, Jonathan L. ;
Wilson, Elizabeth M. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (35) :25801-25816
[2]   METHYLTRIENOLONE, A SPECIFIC LIGAND FOR CELLULAR ANDROGEN RECEPTORS [J].
BONNE, C ;
RAYNAUD, JP .
STEROIDS, 1975, 26 (02) :227-232
[3]   COMPARISON OF 3 METHODS OF ASSESSING SEX-DRIVE IN YEARLING BEEF BULLS AND RELATIONSHIPS WITH TESTOSTERONE AND LH LEVELS [J].
CHENOWETH, PJ ;
BRINKS, JS ;
NETT, TM .
THERIOGENOLOGY, 1979, 12 (04) :223-233
[4]   SPECIES DISTRIBUTION OF TESTOSTERONE-BINDING GLOBULIN [J].
CORVOL, P ;
BARDIN, CW .
BIOLOGY OF REPRODUCTION, 1973, 8 (03) :277-282
[5]   DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer [J].
D'Antonio, Jason M. ;
Griend, Donald J. Vander ;
Isaacs, John T. .
ENDOCRINE-RELATED CANCER, 2009, 16 (02) :325-332
[6]   STEROID-LEVELS IN CANCER OF THE PROSTATE - MARKERS OF TUMOR DIFFERENTIATION AND ADEQUACY OF ANTI-ANDROGEN THERAPY [J].
GELLER, J ;
ALBERT, J ;
LOZA, D .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1979, 11 (01) :631-636
[7]   A SERUM-FREE DEFINED MEDIUM CAPABLE OF SUPPORTING GROWTH OF 4 ESTABLISHED HUMAN PROSTATIC-CARCINOMA CELL-LINES [J].
HEDLUND, TE ;
MILLER, GJ .
PROSTATE, 1994, 24 (05) :221-228
[8]   Suppression of mutant androgen receptors by flutamide [J].
Ishioka, Junichiro ;
Hara, Shuntaro ;
Isaacs, John T. ;
Tomura, Arihiro ;
Nishikawa, Kiyohiro ;
Kageyama, Yukio .
INTERNATIONAL JOURNAL OF UROLOGY, 2009, 16 (05) :516-521
[9]   RESPONSE OF RAT AND HUMAN PROSTATIC CANCERS TO THE NOVEL 5-ALPHA-REDUCTASE INHIBITOR, SK-AND-F 105657 [J].
LAMB, JC ;
LEVY, MA ;
JOHNSON, RK ;
ISAACS, JT .
PROSTATE, 1992, 21 (01) :15-34
[10]  
LAMOTHE P, 1972, CAN J COMPARAT MED, V36, P94